Want to see HK:1061 full AI Analyst Report?
Top Page
Essex Bio-Technology
(1061)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$2.50
▲(11.61% Upside)
Action:Reiterated
Date:10/21/26
The score is driven primarily by strong underlying financial quality (high profitability and improving, low leverage) and very attractive valuation (low P/E and high dividend yield). These positives are moderated by weaker technicals (below key moving averages with negative MACD) and volatility in free cash flow, which adds execution and sustainability risk.
Positive Factors
High, stable profitability
Exceptionally high and stable gross margins, combined with solid EBIT profitability, indicate strong economics across the company’s biologic and ophthalmology product portfolio. This provides a durable base for funding research, manufacturing, commercialization, and other strategic investments.
Negative Factors
Choppy revenue performance
Uneven revenue performance reduces visibility into the company’s underlying growth trajectory and suggests that demand or commercial execution has not been consistently improving. Continued volatility could make it harder to scale fixed capabilities and sustain current profitability over time.
Read all positive and negative factors
Positive Factors
Negative Factors
High, stable profitability
Exceptionally high and stable gross margins, combined with solid EBIT profitability, indicate strong economics across the company’s biologic and ophthalmology product portfolio. This provides a durable base for funding research, manufacturing, commercialization, and other strategic investments.
Read all positive factors
Essex Bio-Technology (1061) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.19B
Dividend Yield5.74%
Average Volume (3M)161.85K
Price to Earnings (P/E)4.4
Beta (1Y)0.28
Revenue Growth-0.74%
EPS Growth-15.21%
CountryHK
Employees1,240
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.47
Shares Outstanding567,006,000
10 Day Avg. Volume137,000
30 Day Avg. Volume161,851
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)0.89
Price to Sales (P/S)1.18
P/FCF Ratio16.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.57
Revenue Forecast (FY)HK$1.87B
Essex Bio-Technology Business Overview & Revenue Model
Company Description
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and ...
Essex Bio-Technology Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.72B | 1.81B | 1.67B | 1.71B | 1.32B | 1.64B |
| Gross Profit | 1.50B | 1.62B | 1.50B | 1.54B | 1.19B | 1.40B |
| EBITDA | 407.97M | 479.37M | 410.66M | 418.74M | 313.92M | 436.65M |
| Net Income | 265.41M | 318.09M | 307.22M | 275.26M | 225.41M | 345.97M |
Balance Sheet | ||||||
| Total Assets | 3.62B | 3.49B | 2.98B | 2.83B | 2.71B | 2.86B |
| Cash, Cash Equivalents and Short-Term Investments | 807.73M | 784.14M | 560.74M | 515.03M | 543.49M | 671.35M |
| Total Debt | 348.99M | 346.90M | 187.04M | 294.02M | 489.73M | 565.19M |
| Total Liabilities | 1.07B | 1.08B | 859.33M | 903.78M | 981.03M | 1.13B |
| Stockholders Equity | 2.55B | 2.41B | 2.12B | 1.92B | 1.73B | 1.73B |
Cash Flow | ||||||
| Free Cash Flow | 153.63M | 131.71M | 324.07M | 211.16M | 99.87M | 164.63M |
| Operating Cash Flow | 284.95M | 306.32M | 368.47M | 339.21M | 382.79M | 409.16M |
| Investing Cash Flow | -102.44M | -165.17M | -106.59M | -54.34M | -302.03M | -280.08M |
| Financing Cash Flow | -46.53M | 62.10M | -200.81M | -309.92M | -169.11M | -73.13M |
Essex Bio-Technology Technical Analysis
Neutral
2.24
Price Trends
2.14
Negative
2.35
Negative
2.93
Negative
Market Momentum
-0.03
Negative
48.74
Neutral
61.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1061, the sentiment is Neutral. The current price of 2.24 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 2.14, and below the 200-day MA of 2.93, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.74 is Neutral, neither overbought nor oversold. The STOCH value of 61.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1061.
Essex Bio-Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$1.19B | 4.45 | 10.70% | 5.74% | -0.74% | -15.21% | |
70 Outperform | HK$1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% | |
68 Neutral | HK$606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% | |
59 Neutral | HK$1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$2.11B | -18.09 | -10.61% | ― | 83.49% | -110.21% | |
42 Neutral | HK$1.59B | -5.37 | -33.42% | ― | ― | ― |
* Healthcare Sector Average
HK:1061
Essex Bio-Technology
2.09
-2.09
-49.95%
HK:2552
Hua Medicine
2.18
-1.44
-39.75%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.03
-0.77
-42.94%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
0.92
-0.20
-17.86%
HK:2633
Jacobson Pharma Corporation Limited
0.94
-0.42
-30.74%
HK:2561
VISEN Pharmaceuticals
13.93
-24.67
-63.91%
Essex Bio-Technology Corporate Events
Essex Bio-Technology Reports Profit Decline but Strong Balance Sheet in First-Half 2026
Aug 5, 2026
Essex Bio-Technology reported a weaker first half for 2026, with turnover falling 10.5% to HK$784.7 million and profit for the period dropping 32.2% to HK$110.7 million, reflecting pressure on margins as gross profit margin slipped to 83.6% and ne...
Essex Bio-Technology Declares Interim Dividend for First Half of 2026
Aug 5, 2026
Essex Bio-Technology Limited has declared an interim ordinary cash dividend of HKD 0.05 per share for the six months ended 30 June 2026. The dividend, relating to the financial year ending 31 December 2026, will be paid in Hong Kong dollars with n...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.